


Attorney Docket No.: PB60754USw

Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Original) A compound of formula (I);



wherein:


Y is phenyl, unsubstituted or substituted with one, two or three substituents;

R¹ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or halosubstituted C₁₋₆ alkyl;

R² is (CH₂)_mR³ where m is 0 or 1;

or R¹ and R² together with N to which they are attached form an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl ring;


R³ is hydrogen, an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl group, an unsubstituted or substituted C₃₋₈ cycloalkyl group, an unsubstituted or substituted straight or branched C₁₋₁₀ alkyl, an unsubstituted or substituted C₅₋₇ cycloalkenyl, R⁵; or R³ is an unsubstituted or substituted 5- to 6- membered aromatic heterocyclyl group, or group A:



Attorney Docket No.: PB60754USw

R^4 is selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, or halosubstituted C_{1-6} alkyl, $COCH_3$, or SO_2Me ;

R^5 is



wherein p is 0, 1 or 2, and X is CH_2 , O, S, SO or SO_2 ;

R^6 is halo, an substituted or unsubstituted (C_{1-6}) alkyl, (C_{3-6}) cycloalkyl, 4- to 7- membered non aromatic heterocyclyl group;

R^7 is OH, C_{1-6} alkoxy, $NR^{8a}R^{8b}$, $NHCO R^9$, $NHSO_2R^9$, SO_qR^9 ;

R^{8a} is H or C_{1-6} alkyl;

R^{8b} is H or C_{1-6} alkyl;

R^9 is C_{1-6} alkyl;

R_a is independently selected from hydrogen, fluoro, chloro or trifluoromethyl;

R_b is independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy, hydroxy, cyano, halo, sulfonyl, $CONH_2$, $COOH$ or $NHCOOC_{1-6}$ alkyl;


R^{12} is hydrogen or C_{1-6} alkyl;

q is 0, 1 or 2;

or a pharmaceutically acceptable derivative thereof,

wherein the compound is not (5-([bis-(2-methoxy-ethyl)-amino]-methyl)-4-trifluoromethyl-pyrimidin-2-yl)-(3-chlorophenyl)-amine or {1-[2-(3-chlorophenylamino)-4-trifluoromethyl-pyrimidin-5-ylmethyl]-piperidin-4-yl}-methanol, formate.

2. (Original) A compound as claimed in Claim 1 wherein the compound of formula (I) is a compound of formula (Ia):



Attorney Docket No.: PB60754USw

wherein;

R^1 is selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl and halosubstituted C_{1-6} alkyl;


R^2 is $(CH_2)_m R^3$ where m is 0 or 1;

or R^1 and R^2 together with N to which they are attached form a 4- to 8-membered non- aromatic ring selected from azetidiny, pyrrolidiny, morpholiny, piperiziny, piperidiny, thiomorpholiny, tetrahydropyridiny, azapine, oxapine, azacyclooctany, azaoxacyclooctany and azathiacyclooctany any of which can be unsubstituted or substituted by one, two or three substituents selected from C_{1-6} alkyl, C_{1-6} alkylOH, C_{1-6} alkoxy, a hydroxy group, a cyano group, halo, sulfonyl group, methylsulfonyl, $NR^{8a}R^{8b}$, $NHCOCH_3$, $(=O)$, $-CONHCH_3$ and $NHSO_2CH_3$, $C(O)OC_{1-6}alkyl$;

R^3 is hydrogen, 2- or 3- azetidiny, oxetany, thioxetany, thioxetany-s-oxide, thioxetany-s,s-dioxide, dioxalany, pyrrolidiny, tetrahydrofurany, tetrahydrothiopheny, tetrahydrothiopheny-s-oxide, tetrahydrothiopheny-s,s-dioxide, morpholiny, piperidiny, piperaziny, tetrahydropyrany, tetrahydrothiopyrany, tetrahydrothiopyrany-s-dioxide, tetrahydrothiopyrany-s,s-dioxide, thiomorpholiny, thiomorpholiny-s,s-dioxide, tetrahydropyridiny, dioxany, tetrahydrothiopyran 1,1 dioxide, azapine, oxapine, azacyclooctany, azaoxacyclooctany, azathiacyclooctany, oxacyclooctany, thiacyclooctany, a C_{3-8} cycloalkyl group, a straight or branched C_{1-10} alkyl, a C_{5-7} cycloalkenyl or R^5 , any of which can be unsubstituted or substituted by one, two or three substituents selected from C_{1-6} alkyl, C_{1-6} alkoxy, a hydroxy group, a cyano group, halo, sulfonyl group, methylsulfonyl, $NR^{8a}R^{8b}$, $NHCOCH_3$, $(=O)$, and $-CONHCH_3$ and when R^3 is alkyl it can be phenyl or phenyl substituted by halo, hydroxy or cyano;


or R^3 is group A or selected from furany, dioxalany, pyrroly, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, triazinyl, isothiazolyl, isoxazolyl, thienyl, pyrazolyl, tetrazolyl, pyridiny, pyriziny, pyrimidiny, pyraziny, triazinyl, or tetraziny any of which can be unsubstituted or substituted by one, two or three substituents selected from C_{1-6} alkyl, C_{1-6} alkoxy, a hydroxy group, a cyano group, halo, sulfonyl group, methylsulfonyl, $NR^{8a}R^{8b}$, $NHCOCH_3$, $(=O)$, and $-CONHCH_3$;

Attorney Docket No.: PB60754USw



R¹¹ is selected from C₁₋₆ alkyl, halosubstituted C₁₋₆ alkyl, C₁₋₆ alkoxy, a hydroxy group, a cyano group, halo, a C₁₋₆alkyl sulfonyl group, -CONH₂, -NHCOC₁₋₆alkyl, -COOH, -CH₂COOH, halosubstituted C₁₋₆ alkoxy, SC₁₋₆alkyl and SO₂NR^{8a}R^{8b};

R⁴ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or halosubstituted C₁₋₆ alkyl, COCH₃, and SO₂Me;

 R^5 is

wherein p is 0, 1 or 2 and X is CH₂, O, S, SO or SO₂;

R^6 is halo, a substituted or unsubstituted (C_{1-6}) alkyl, (C_{3-6}) cycloalkyl, 4- to 7- membered non aromatic heterocyclyl group;

R^7 is OH, C_{1-6} alkoxy, $NR^{8a}R^{8b}$, $NHCOR^9$, $NHSO_2R^9$, SO_2R^9 .

R^{8a} is H or C_{1-6} alkyl;

R^{ab} is H or C_{1-6} alkyl;

R^9 is C_{1-6} alkyl;

R^{12} is hydrogen or C_{1-6} alkyl;

Ra is independently selected from hydrogen, fluoro, chloro or trifluoromethyl;

Rb is independently selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, haloC₁₋₆ alkoxy, hydroxy, cyano, halo, sulfonyl, CONH₂, COOH or NHCOOC₁₋₆ alkyl;

q is 0, 1 or 2;


d is 0, 1, 2 or 3

or a pharmaceutically acceptable derivative thereof

Attorney Docket No.: PB60754USw

wherein the compound is not
(5-[[bis-(2-methoxy-ethyl)-amino]-methyl]-4-trifluoromethyl-pyrimidin-2-yl)-(3-chlorophenyl)-amine or {1-[2-(3-chloro-phenylamino)-4-trifluoromethyl-pyrimidin-5-ylmethyl]-piperidin-4-yl}-methanol, formate.

3. (Original) A compound as claimed in Claim 1 wherein the compound of formula (I) is a compound of formula (Ib):



wherein;

R^1 is hydrogen or methyl;

R^3 is an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl group an unsubstituted or substituted C_{3-8} cycloalkyl group, an unsubstituted or substituted straight or branched C_{1-10} alkyl;

R^6 is an substituted or unsubstituted (C_{1-6})alkyl, (C_{3-6})cycloalkyl, or 4- to 7- membered non aromatic heterocyclyl group;

R^{11} is selected from halo, cyano, methyl, trifluoromethyl, methoxy, trifluoromethoxy or SCH_3 ;


d is 0, 1, 2 or 3;

or a pharmaceutically acceptable derivative thereof wherein the compound is not

{1-[2-(3-chloro-phenylamino)-4-trifluoromethyl-pyrimidin-5-ylmethyl]-piperidin-4-yl}-methanol, formate.

4. (Original) A compound as claimed in Claim 1 wherein the compound of formula (I) is a compound of formula (Ic):


Attorney Docket No.: PB60754USw



wherein

R^1 is hydrogen or methyl.

R^3 is group A, pyridinyl, or pyrimidinyl, any of which can be optionally substituted;



R_a is independently selected from hydrogen, fluoro, chloro or trifluoromethyl;

R_b is independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy, hydroxy, cyano, halo, sulfonyl, $CONH_2$, $COOH$ or $NHCOOC_{1-6}$ alkyl;

R^6 is an substituted or unsubstituted (C_{1-6})alkyl, (C_{3-6})cycloalkyl or 4- to 7- membered non aromatic heterocyclyl group;

R^{11} is selected from halo, cyano, methyl, trifluoromethyl, methoxy, trifluoromethoxy SCH_3 ;

d is 0, 1, 2 or 3;

or a pharmaceutically acceptable derivative thereof.

5. (Currently Amended) A compound as claimed in ~~any one of~~ claims 1 to 4 wherein R^6 is either cyclopropyl, isopropyl, tert-butyl or trifluoromethyl.

6. Canceled.

Attorney Docket No.: PB60754USw

7. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in ~~any one of claims 1 to 6~~ or a pharmaceutically acceptable derivative thereof and a pharmaceutical carrier or diluent thereof.
8. (Currently Amended) A pharmaceutical composition as claimed in claim 7 further comprising a second therapeutic agent.
9. (Currently Amended) A method of treating a mammal suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) as claimed in ~~any one of claims 1 to 6~~ or a pharmaceutically acceptable derivative thereof.
10. (Currently Amended) A compound of formula (I) as claimed in ~~any one of claims 1 to 6~~ or a pharmaceutically acceptable derivative thereof for use as a medicament in the treatment of pain.
11. (New) A pharmaceutical composition comprising a compound as claimed in claim 1 or a pharmaceutical derivative thereof and at least one Cox-2 inhibitor.
12. (New) A pharmaceutical composition comprising a compound as claimed in claim 1 or a pharmaceutical derivative thereof and at least one PDE4 inhibitor.
13. (New) The method of claim 9 wherein the condition is selected from an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis.